On Friday, Perspective Therapeutics Inc (AMEX: CATX) opened lower -4.35% from the last session, before settling in for the closing price of $2.30. Price fluctuations for CATX have ranged from $2.22 to $19.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1.39%. Company’s average yearly earnings per share was noted -5.46% at the time writing. With a float of $53.97 million, this company’s outstanding shares have now reached $70.67 million.
Let’s determine the extent of company efficiency that accounts for 140 employees. In terms of profitability, gross margin is 100.0%, operating margin of -15937.09%, and the pretax margin is -13973.89%.
Perspective Therapeutics Inc (CATX) Insider Activity
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Perspective Therapeutics Inc is 27.12%, while institutional ownership is 68.21%. The most recent insider transaction that took place on Dec 04 ’24, was worth 100,004. In this transaction Director of this company bought 25,975 shares at a rate of $3.85, taking the stock ownership to the 25,975 shares. Before that another transaction happened on Dec 04 ’24, when Company’s CEO bought 8,000 for $3.77, making the entire transaction worth $30,132. This insider now owns 36,257 shares in total.
Perspective Therapeutics Inc (CATX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.76% during the next five years compared to -9.86% drop over the previous five years of trading.
Perspective Therapeutics Inc (AMEX: CATX) Trading Performance Indicators
Check out the current performance indicators for Perspective Therapeutics Inc (CATX). In the past quarter, the stock posted a quick ratio of 12.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 112.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Perspective Therapeutics Inc (CATX)
Looking closely at Perspective Therapeutics Inc (AMEX: CATX), its last 5-days average volume was 0.56 million, which is a drop from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 8.07%. Additionally, its Average True Range was 0.20.
During the past 100 days, Perspective Therapeutics Inc’s (CATX) raw stochastic average was set at 0.09%, which indicates a significant decrease from 1.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.59% in the past 14 days, which was lower than the 140.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.94, while its 200-day Moving Average is $8.46. However, in the short run, Perspective Therapeutics Inc’s stock first resistance to watch stands at $2.32. Second resistance stands at $2.43. The third major resistance level sits at $2.50. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $2.07. Should the price break the second support level, the third support level stands at $1.96.
Perspective Therapeutics Inc (AMEX: CATX) Key Stats
There are currently 74,052K shares outstanding in the company with a market cap of 162.91 million. Presently, the company’s annual sales total 1,430 K according to its annual income of -46,510 K. Last quarter, the company’s sales amounted to 370 K and its income totaled -15,120 K.
